Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 47

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 47
---
 stockholders may ultimately convert or exercise and sell all or a portion of the full amount issuable upon exercise.
If all derivative securities outstanding as of July 2, 2025 were converted or exercised into shares of common stock, there would be an
additional 2,264,707 shares of common stock outstanding as a result. The issuance of these shares will have the effect of further
diluting the proportionate equity interest and voting power of holders of our common stock.

The price of our common stock may be volatile, and you may be unable to resell your shares at or above the offering price.

The trading price of our common stock following
this offering may fluctuate substantially. Following the closing of this public offering, the market price of our common stock may be
higher or lower than the price you pay in the offering, depending on many factors, some of which are beyond our control and may not be
related to our operating performance. These fluctuations could cause you to lose all or part of your investment in our common stock. Factors
that could cause fluctuations in the trading price of our common stock include the following:

| ● | limited trading volume; |

| ● | actual or anticipated fluctuations in our financial condition and operating results; |

| ● | actual or anticipated changes in our growth rate relative to our competitors; |

| ● | commercial success and market acceptance of our product; |

| ● | success of our competitors in developing or commercializing products; |

| ● | ability to commercialize or obtain regulatory approvals for our product, or delays in commercializing or obtaining regulatory approvals; |

| ● | strategic transactions undertaken by us; |

| ● | additions or departures of key personnel; |

| ● | prevailing economic conditions; |

| ● | disputes concerning our intellectual property or other proprietary rights; |

| ● | FDA or other U.S. or foreign regulatory actions affecting us or the pharmaceutical industry; |

| ● | sales of our common stock by our officers, directors or significant stockholders; |

<div align='center'>22</div>

| ● | future sales or issuances of equity or debt securities by us; |

| ● | business disruptions caused by earthquakes, fires or other natural disasters; |

| ● | the exercise and sale of any outstanding warrants or options, including the exercise of the Warrants issued in this offering; |

| ● | changes in our Board or management; |

| ● | issuance of new or changed securities analysts’ reports or recommendations regarding us; |

| ● | any future COVID